Y-mAbs Therapeutics Inc (NAS:YMAB)
$ 12.39 -0.34 (-2.67%) Market Cap: 543.71 Mil Enterprise Value: 484.06 Mil PE Ratio: 0 PB Ratio: 5.48 GF Score: 56/100

Y-mAbs Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 11, 2023 / 10:15PM GMT
Release Date Price: $4.58 (-1.08%)
Tessa Thomas Romero
JPMorgan Chase & Co, Research Division - Associate

Welcome, everyone, to the 41st Annual JPMorgan Healthcare Conference. My name is Tessa Romero. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Taylor Hanley and Adhiraj Chauhan from the team.

Our next presenting company is Y-mAbs Therapeutics. And speaking on behalf of the company, we have Founder, Thomas Gad.

Before I turn it over to Thomas, I just wanted to highlight for that -- for the Q&A after this formal presentation, there is an ask-a-question button in the portal, and I'm happy to ask the question on your behalf. We will also be taking live questions here in the room.

So with that, Thomas, over to you.

Thomas Gad
Y-mAbs Therapeutics, Inc. - Founder, Interim CEO, President, Head of Business Development & Strategy and Director

Hello, everyone, and thank you for listening into today's presentation of Y-mAbs Therapeutics. Y-mAbs is a commercial-stage biopharmaceutical company founded on technology spun out of Memorial

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot